Full-year earnings forecast has been significantly revised to net sales of 21,700 million yen, operating loss of -1,500 million yen, and net loss of -2,500 million yen attributable to owners of the parent. Second-quarter results fell short of prior forecasts, and the dividend has been revised to nil at year-end. Priority is placed on stabilizing the financial base and restoring cash-generation capability.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7600","jir_company_name":"Japan Medical Dynamic Marketing, INC.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/7600-20261104-03.pdf","jir_short_summary":"Full-year earnings forecast has been significantly revised to net sales of 21,700 million yen, operating loss of -1,500 million yen, and net loss of -2,500 million yen attributable to owners of the parent. Second-quarter results fell short of prior forecasts, and the dividend has been revised to nil at year-end. Priority is placed on stabilizing the financial base and restoring cash-generation capability.","jir_summary":"### Performance Overview\nThe consolidated full-year earnings forecast for the fiscal year ending March 2027 has been comprehensively revised downward. Net sales are expected to decrease by 3,670 million yen from the previous forecast, and operating income, ordinary income, and net income attributable to owners of the parent are also expected to decline by approximately 1,500\u20132,500 million yen respectively. Second-quarter results fell short of prior forecasts due to weakened domestic market demand and reduced competitiveness in the U.S. market, and the reversal of deferred tax assets also had an impact. The dividend forecast has been revised to no dividend at year-end. The company will prioritize stabilizing its financial base and recovering cash-generation capability.\n\n### Shareholder Returns and Outlook\nGiven the deterioration in performance and the forecasted negative free cash flow, the company will prioritize securing liquidity and normalizing the financial base while maintaining its shareholder return policy. The timing of resuming dividends will be determined based on second-half recovery, reforms at the U.S. subsidiary, inventory optimization, and progress in selective and concentrated investments.","jir_financial_highlights":"Net Sales: 21,700 million yen (Previous forecast 25,370 million yen \u2192 -3,670 million yen)\nOperating Income: -1,500 million yen (Previous forecast -430 million yen \u2192 -1,500 million yen)\nOrdinary Income: -1,750 million yen (Previous forecast -140 million yen \u2192 -1,750 million yen)\nNet Income Attributable to Owners of Parent: -2,500 million yen (Previous forecast 60 million yen \u2192 -2,500 million yen)\nNet Income Per Share: -94.86 yen (Previous forecast 2.28 yen \u2192 -94.86 yen)\nDividend: Annual 0 yen Second quarter-end 0 yen Year-end 0 yen Total 0 yen (Previous forecast 17 yen 00 sen Total 17 yen 00 sen \u2192 revised to nil)","jir_category":"","jir_hashtags":"#JapanMedicalDynamicMarketing, #EarningsRevision, #DividendPolicyChange","jir_key_figures":"Net Sales: 21,700 million yen\nOperating Income: -1,500 million yen\nNet Income Attributable to Owners of Parent: -2,500 million yen","jir_meta_title":"Japan Medical Dynamic Marketing, INC. Announces Revision of Fiscal Year Ending March 2027 Second Quarter Earnings and Dividend Policy","jir_meta_description":"Japan Medical Dynamic Marketing, INC. has downwardly revised its consolidated earnings forecast for the fiscal year ending March 2027. Net sales are 21,700 million yen, operating loss -1,500 million yen, and the year-end dividend has been revised to nil. The company prioritizes financial stabilization. See IR materials for details.","jir_og_title":"Japan Medical Dynamic Marketing, INC. Announces Earnings Revision and Move to No Dividend","jir_og_description":"Japan Medical Dynamic Marketing, INC. has significantly revised its earnings forecast for the second quarter of the fiscal year ending March 2027 and has revised its dividend to nil. The company discloses plans for financial stabilization and growth investment.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58545,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141200","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n